Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7487.084 | 0.0038 | -0.9688 | 1.3396 | |
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7487.084 | 0.0020 | -0.9804 | 1.3396 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7489.084 | 1.0165 | 1.0162 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7489.084 | 1.0333 | 1.0326 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7489.084 | 1.0661 | 1.0642 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7489.084 | 1.0504 | 1.0491 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7489.084 | 0.9193 | 0.9187 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7489.084 | 0.7912 | 0.7818 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7489.084 | 0.2961 | 0.0975 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7489.084 | 0.0070 | -0.8273 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7489.084 | 0.0028 | -0.8904 | 2.0279 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7490.085 | 0.9482 | 0.9591 | 2.5778 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7490.085 | 0.9571 | 0.9663 | 2.5778 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7490.085 | 0.9633 | 0.9712 | 2.5778 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7490.085 | 1.0128 | 1.0099 | 2.5778 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7490.085 | 1.0505 | 1.0386 | 2.5778 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7490.085 | 0.9639 | 0.9716 | 2.5778 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7490.085 | 0.9416 | 0.9539 | 2.5778 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7490.085 | 0.1621 | -0.0127 | 2.5778 | |
| MCF12A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7490.085 | 0.0075 | -0.7001 | 2.5778 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7492.084 | 0.9376 | 0.9151 | 1.4850 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7492.084 | 1.0134 | 1.0180 | 1.4850 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7492.084 | 0.9844 | 0.9789 | 1.4850 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7492.084 | 0.9774 | 0.9694 | 1.4850 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7492.084 | 0.9502 | 0.9323 | 1.4850 |